Nicholas Theodosakis, M.D.
This page shows the publications co-authored by Nicholas Theodosakis and Yevgeniy Semenov.
Title: Immune-checkpoint inhibitor therapy is underutilized in the US: A multi-institutional cohort analysis. Immunol Lett. 2021 Dec 30; 244:43-44.
Reply to: COVID-19 vaccination in IMID patients receiving rituximab: a personalized regimen should be formulated. J Am Acad Dermatol. 2022 Mar 29.
Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts. J Am Acad Dermatol. 2022 01; 86(1):252-255.
Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist. 2021 05; 26(5):e898-e901.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.